| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Biochemistry and Molecular Genetics, and
Division of Hematology/Oncology and Hematologic Malignancy Program, University of Virginia School of Medicine, Charlottesville, VA 22908
Complement plays an important role in the immunotherapeutic action of the anti-CD20 mAb rituximab, and therefore we investigated whether complement might be the limiting factor in rituximab therapy. Our in vitro studies indicate that at high cell densities, binding of rituximab to human CD20+ cells leads to loss of complement activity and consumption of component C2. Infusion of rituximab in chronic lymphocytic leukemia patients also depletes complement; sera of treated patients have reduced capacity to C3b opsonize and kill CD20+ cells unless supplemented with normal serum or component C2. Initiation of rituximab infusion in chronic lymphocytic leukemia patients leads to rapid clearance of CD20+ cells. However, substantial numbers of B cells, with significantly reduced levels of CD20, return to the bloodstream immediately after rituximab infusion. In addition, a mAb specific for the Fc region of rituximab does not bind to these recirculating cells, suggesting that the rituximab-opsonized cells were temporarily sequestered by the mononuclear phagocytic system, and then released back into the circulation after the rituximab-CD20 complexes were removed by phagocytic cells. Western blots provide additional evidence for this escape mechanism that appears to occur as a consequence of CD20 loss. Treatment paradigms to prevent this escape, such as use of engineered or alternative anti-CD20 mAbs, may allow for more effective immunotherapy of chronic lymphocytic leukemia.
This article has been cited by other articles:
|
|
 |
|
  F. Morschhauser, J. P. Leonard, L. Fayad, B. Coiffier, M.-O. Petillon, M. Coleman, S. J. Schuster, M. J.S. Dyer, H. Horne, N. Teoh, et al. Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results J. Clin. Oncol., July 10, 2009; 27(20): 3346 - 3353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Pawluczkowycz, F. J. Beurskens, P. V. Beum, M. A. Lindorfer, J. G. J. van de Winkel, P. W. H. I. Parren, and R. P. Taylor Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX J. Immunol., July 1, 2009; 183(1): 749 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Hayden-Ledbetter, C. G. Cerveny, E. Espling, W. A. Brady, L. S. Grosmaire, P. Tan, R. Bader, S. Slater, C. A. Nilsson, D. S. Barone, et al. CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells Clin. Cancer Res., April 15, 2009; 15(8): 2739 - 2746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.P. Taylor Use of fresh frozen plasma to enhance the therapeutic action of rituximab QJM, December 1, 2008; 101(12): 991 - 991. [Full Text] [PDF]
|
|
|
|
|
|
P. V. Beum, D. A. Mack, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes J. Immunol., December 1, 2008; 181(11): 8120 - 8132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schattner and A. Klepfish Response QJM, December 1, 2008; 101(12): 991 - 992. [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Beurskens, S. R. Ruuls, P. J. Engelberts, T. Vink, W. J. Mackus, J. G. J. van de Winkel, and P. W. H. I. Parren Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies Blood, November 15, 2008; 112(10): 4354 - 4355. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Mattes, R. M. Sharkey, H. Karacay, M. S. Czuczman, and D. M. Goldenberg Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab) Clin. Cancer Res., October 1, 2008; 14(19): 6154 - 6160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Klepfish, E.A. Rachmilewitz, I. Kotsianidis, P. Patchenko, and A. Schattner Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL QJM, September 1, 2008; 101(9): 737 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhou, W. Hu, and X. Qin The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy Oncologist, September 1, 2008; 13(9): 954 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. V. Beum, M. A. Lindorfer, and R. P. Taylor Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving J. Immunol., August 15, 2008; 181(4): 2916 - 2924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. V. Beum, M. A. Lindorfer, F. Beurskens, P. T. Stukenberg, H. M. Lokhorst, A. W. Pawluczkowycz, P. W. H. I. Parren, J. G. J. van de Winkel, and R. P. Taylor Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis J. Immunol., July 1, 2008; 181(1): 822 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Natsume, M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, K. Shitara, et al. Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities Cancer Res., May 15, 2008; 68(10): 3863 - 3872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-Y. Wang, E. Racila, R. P. Taylor, and G. J. Weiner NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement Blood, February 1, 2008; 111(3): 1456 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Macor, C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, and F. Tedesco In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab Cancer Res., November 1, 2007; 67(21): 10556 - 10563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Pawluczkowycz, M. A. Lindorfer, J. N. Waitumbi, and R. P. Taylor Hematin Promotes Complement Alternative Pathway-Mediated Deposition of C3 Activation Fragments on Human Erythrocytes: Potential Implications for the Pathogenesis of Anemia in Malaria J. Immunol., October 15, 2007; 179(8): 5543 - 5552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, M. E. Williams, J. B. Cousar, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models J. Immunol., September 15, 2007; 179(6): 4263 - 4271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Jazirehi, M. I. Vega, and B. Bonavida Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy Cancer Res., February 1, 2007; 67(3): 1270 - 1281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Williams, J. J. Densmore, A. W. Pawluczkowycz, P. V. Beum, A. D. Kennedy, M. A. Lindorfer, S. H. Hamil, J. C. Eggleton, and R. P. Taylor Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia J. Immunol., November 15, 2006; 177(10): 7435 - 7443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Teeling, W. J. M. Mackus, L. J. J. M. Wiegman, J. H. N. van den Brakel, S. A. Beers, R. R. French, T. van Meerten, S. Ebeling, T. Vink, J. W. Slootstra, et al. The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20 J. Immunol., July 1, 2006; 177(1): 362 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Alfonso-Perez, S. Lopez-Giral, N. E. Quintana, J. Loscertales, P. Martin-Jimenez, and C. Munoz Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia J. Leukoc. Biol., June 1, 2006; 79(6): 1157 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. V. Beum, A. D. Kennedy, M. E. Williams, M. A. Lindorfer, and R. P. Taylor The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes J. Immunol., February 15, 2006; 176(4): 2600 - 2609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Israel, M. Gulley, S. Elmore, S. Ferrini, W.-h. Feng, and S. C. Kenney Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas Mol. Cancer Ther., December 1, 2005; 4(12): 2037 - 2044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Imai, C. Landen, R. Ohta, N.-K. V. Cheung, and S. Tomlinson Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer Cancer Res., November 15, 2005; 65(22): 10562 - 10568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Niwa, M. Sakurada, Y. Kobayashi, A. Uehara, K. Matsushima, R. Ueda, K. Nakamura, and K. Shitara Enhanced Natural Killer Cell Binding and Activation by Low-Fucose IgG1 Antibody Results in Potent Antibody-Dependent Cellular Cytotoxicity Induction at Lower Antigen Density Clin. Cancer Res., March 15, 2005; 11(6): 2327 - 2336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Craig, J. N. Waitumbi, and R. P. Taylor Processing of C3b-Opsonized Immune Complexes Bound to Non-Complement Receptor 1 (CR1) Sites on Red Cells: Phagocytosis, Transfer, and Associations with CR1 J. Immunol., March 1, 2005; 174(5): 3059 - 3066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Taylor CD20 Trek: the next generation Blood, September 15, 2004; 104(6): 1592 - 1592. [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Olszewski and M. L. Grossbard Empowering Targeted Therapy: Lessons from Rituximab Sci. Signal., July 13, 2004; 2004(241): pe30 - pe30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Cragg, M. C. Bayne, T. M. Illidge, T. Valerius, P. W. N. Johnson, M. J. Glennie, I. Jilani, and M. Albitar Apparent modulation of CD20 by rituximab: an alternative explanation Blood, May 15, 2004; 103(10): 3989 - 3991. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
